Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer: A Lifetime Model

Author： Millar J. Alasdair Millward Michael J.

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.25, Iss.5, 2007-01, pp. : 429-442

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer

By Norum Jan

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 12, 2006-08 ,pp. : 1617-1625

Informa Healthcare

Access to resources Recommend Favorite

Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands

By Essers Brigitte A.B. Seferina Shanley C. Tjan-Heijnen Vivianne C.G. Severens Johan L. Novák Annoesjka Pompen Marjolein Oron Ulrich H. Joore Manuela A.

Value in Health, Vol. 13, Iss. 4, 2010-06 ,pp. : 375-380

Blackwell Publishing

Access to resources Recommend Favorite

Trastuzumab: A Review of its Use as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

By Garnock-Jones Karly P. Keating Gillian M. Scott Lesley J.

Drugs, Vol. 70, Iss. 2, 2010-01 ,pp. : 215-239

Adis International

Access to resources Recommend Favorite

Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer: A UK Perspective Considering Duration of Benefit, Long-Term Toxicity and Pattern of Recurrence

By Hall Peter S. Hulme Claire McCabe Christopher Oluboyede Yemi Round Jeff Cameron David A.

PharmacoEconomics, Vol. 29, Iss. 5, 2011-05 ,pp. : 415-432

Adis International

Access to resources Recommend Favorite

Adjuvant Treatment of Early Breast Cancer in the Elderly

Medicinal Chemistry, Vol. 12, Iss. 3, 2016-05 ,pp. : 280-284

Bentham Science Publishers

Access to resources Recommend Favorite